SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 2084498
• 负责人: MICHAEL R GREVER
• 金额: $ 45.76万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2084498
• 关键词: adenocarcinoma; antineoplastics; azacitidine; bone marrow transplantation; breast neoplasms; cancer prevention; cis platinum compound; clinical trials; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; dacarbazine; deoxycoformycin; doxorubicin; drug adverse effect; drug interactions; etoposide; fluorouracil; gastrointestinal neoplasms; hairy cell leukemia; head /neck neoplasm; hepatocellular carcinoma; human subject; human therapy evaluation; ifosfamide; immunomodulators; interferon alpha; interleukin 1; interleukin 2; interleukin 3; leukemia; lung neoplasms; lymphokine activated killer cell; melanoma; melphalan; mesothelioma; metastasis; mitomycin C; mitoxantrone; multidrug resistance; multiple myeloma; nasopharyngeal neoplasms; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; ovary neoplasms; paclitaxel; pancreas neoplasms; passive immunization; prognosis; renal cell carcinoma; sarcoma; splenectomy; therapy compliance; tumor necrosis factor alpha; urinary tract neoplasms; uterus neoplasms

This is a multi-disciplinary collaborative research project directed toward the development of more effective methods of prevention, detection, and treatment of human cancer in all its forms. Included in this project are the following programs: 1) the exploration of new therapeutic agents through a wide range of neoplastic diseases in Phase I, II and III studies, and the coincident study of the toxicities of these agents; 2) the exploration of new combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) the involvement of pertinent basis science disciplines such as biochemistry, pharmacology, cellular biology and mathematics in the formulation and execution of specific treatment protocols; 5) the improvement of cancer care in the community at large by using these programs in the educational effort directed at pre- and post- doctoral students, nurses, allied medical personnel and physicians, 6) the correlation and evaluation of biologic studies, and 7) the evaluation of cancer control efforts to as early detection mechanisms. This research effort will be conducted in cooperation with clinical and basic science investigators at other SWOG institutions and the NCI whose collective experience, information and wisdom will be used to design and conduct clinical trials which will answer important questions in the therapy of cancer. The Ohio State University has been a member and active participant in the Southwest Oncology Group for over thirty years. During this period OSU has grown to be the leading contributor in patient accrual for all SWOG institutions.

这是一个多学科合作研究项目 致力于开发更有效的预防方法， 各种形式的人类癌症的检测和治疗。 包含在 本项目有以下方案：1）探索新的 阶段性多种肿瘤疾病的治疗药物 I、II 和 III 研究，以及毒性的同步研究 这些代理人； 2）新旧新组合的探索 努力更有效地利用协同组合的代理人； 3）针对特定肿瘤问题的多模式方法的开发 以最佳方式使用手术、免疫和放射治疗措施 组合； 4）相关基础科学学科的参与 例如生物化学、药理学、细胞生物学和数学 具体治疗方案的制定和执行； 5) 的 通过使用这些方法改善整个社区的癌症护理 针对博士前和博士后的教育工作计划 学生、护士、相关医务人员和医生，6) 生物学研究的相关性和评估，以及7）评估 癌症控制努力作为早期发现机制。 这项研究 将与临床和基础科学合作进行努力 其他 SWOG 机构和 NCI 的调查员，其集体 经验、信息和智慧将被用来设计和实施 临床试验将回答治疗中的重要问题 癌症。 俄亥俄州立大学是该组织的成员和积极参与者 西南肿瘤集团已有三十多年的历史。 在此期间俄勒冈州立大学 已成长为所有 SWOG 患者增长的主要贡献者 机构。